HISUN(SH:600267) Zheng Quan Zhi Xing·2025-06-19 09:54Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has approved the establishment of a joint venture in synthetic biology to enhance management efficiency and decision-making capabilities [1][2]. Group 1: Joint Venture Details - The joint venture will be established between Hai Zheng Pharmaceutical and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., along with its Hong Kong subsidiary, Huizheng International [1]. - Hai Zheng Pharmaceutical plans to contribute 260 million RMB, representing 74.29% of the registered capital, while Huizheng International will contribute 90 million RMB, accounting for 25.71% [2]. - The market value of the assets involved in the investment, as of May 31, 2025, is approximately 243.78 million RMB, and the company will use the taxable value of the physical assets as its contribution [2]. Group 2: Operational Structure - The joint venture will have a board of directors elected by the shareholders' meeting, which is the highest authority of the joint venture [2]. - The joint venture will appoint one manager, who will be hired or dismissed by the board of directors [2]. - The management team is authorized to handle the establishment and asset contribution of the new company, including signing contracts and completing registration [3].